home / stock / tryp:cc / tryp:cc news

TRYP:CC News and Press, Tryp Therapeutics Inc. From 10/20/22

Stock Information
Company Name: Tryp Therapeutics Inc.
Stock Symbol: TRYP:CC
Market: CNQC
Website: tryptherapeutics.com
Menu
TRYP:CC TRYP:CC Quote TRYP:CC Short TRYP:CC News TRYP:CC Articles TRYP:CC Message Board
Get TRYP:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
TRYP:CC - Sen. Cory Booker Pushing for Psychedelics Treatment of Mental Health

The psychedelic story is coming back strong. All after Sen. Cory Booker tweeted, “Massive breakthroughs in medical studies with psilocybin and MDMA are showing strong promise for patients with PTSD, trauma, addiction, and serious depression. In the past, the failed War on Drugs has c...
TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Notes WIPO Publication of International PCT Patent Application

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced that the World Intellectual Property Organization (“WIPO”) published its international patent...

TRYP:CC - Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Enables Potentially Scalable Model For The Broad Roll-Out of Psychedelic Treatments Company Will Host Investor Update Tuesday, October 4 th KELOWNA, British Columbia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF)...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. According to the update, one application, #63/...
TRYP:CC - Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803

KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today a...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Veteran Finance Exec as CFO

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team with the appointment of Jim O’Neill as its chief fina...

TRYP:CC - Tryp Therapeutics Appoints Jim O'Neill as Chief Financial Officer

KELOWNA, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics Inc. (CSE: TRYP) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has ...
TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced that it has retained IMS Investor Relations. According to the announcement, IMS will work with Tryp Therape...

TRYP:CC - Tryp Therapeutics Retains IMS Investor Relations

KELOWNA, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today a...

TRYP:CC - TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT Canada NewsWire SAN DIEGO , July 8, 2022 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company foc...
Previous 10 Next 10